Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -447,600 | -186,200 | -211,600 | -144,600 | -60,100 |
| Depreciation Amortization | 77,400 | 35,600 | 154,100 | 110,700 | 77,400 |
| Income taxes - deferred | -6,400 | -4,700 | -28,600 | 25,500 | 2,600 |
| Accounts receivable | -129,800 | 2,600 | 118,100 | 82,500 | 97,700 |
| Accounts payable and accrued liabilities | 10,900 | 31,000 | -14,000 | -11,800 | -7,600 |
| Other Working Capital | -181,300 | -36,100 | -2,100 | -167,300 | -52,600 |
| Other Operating Activity | 378,400 | -26,200 | -50,000 | -21,900 | -110,300 |
| Operating Cash Flow | $-298,400 | $-184,000 | $-34,100 | $-126,900 | $-52,900 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -27,600 | -15,100 | -115,800 | -92,200 | -64,300 |
| Net Acquisitions | 270,200 | N/A | -243,700 | -243,700 | N/A |
| Purchase Sale Intangibles | N/A | N/A | -21,800 | N/A | N/A |
| Other Investing Activity | 0 | 0 | -21,800 | 0 | 0 |
| Investing Cash Flow | $242,600 | $-15,100 | $-381,300 | $-335,900 | $-64,300 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 0 | 598,000 | 238,000 | -16,900 |
| Debt Repayment | -504,600 | -8,400 | -33,800 | -25,300 | N/A |
| Common Stock Repurchased | N/A | N/A | -82,100 | -81,900 | -81,900 |
| Other Financing Activity | 7,200 | -2,100 | -900 | -2,700 | -2,400 |
| Financing Cash Flow | $-497,400 | $-10,500 | $481,200 | $128,100 | $-101,200 |
| Exchange Rate Effect | -800 | -200 | 500 | -600 | 400 |
| Beginning Cash Position | 642,600 | 642,600 | 576,300 | 576,300 | 576,300 |
| End Cash Position | 88,600 | 430,200 | 642,600 | 241,000 | 358,300 |
| Net Cash Flow | $-554,000 | $-212,400 | $66,300 | $-335,300 | $-218,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | -298,400 | -184,000 | -34,100 | -126,900 | -52,900 |
| Capital Expenditure | -27,600 | -15,100 | -115,800 | -92,200 | -64,300 |
| Free Cash Flow | -326,000 | -199,100 | -149,900 | -219,100 | -117,200 |